Tangen Biosciences is a technology company.
Tangen Biosciences has raised $9.0M across 1 funding round.
Tangen Biosciences has raised $9.0M in total across 1 funding round.
Tangen Biosciences has raised $9.0M in total across 1 funding round.
Tangen Biosciences's investors include Connecticut Innovations, Sway Ventures.
Tangen Biosciences is a molecular diagnostics company founded in 2013 in Branford, Connecticut, developing the TangenDx™ platform—a portable, low-cost system for rapid nucleic acid detection from diverse samples like whole blood, sputum, or swabs[1][2][3][4][5]. It serves healthcare providers, clinics, pharmacies, rural areas, and potentially bioterrorism response by solving the need for fast, sensitive, lab-independent testing for infections like sepsis, COVID-19, antibiotic resistance, and anthrax, targeting the $3B bloodstream infection market with superior speed (under 1 hour), multi-target capability (up to 33 targets per sample), and simplicity over PCR or culture methods[1][2][3][4]. Growth includes BARDA funding for COVID-19 tests, USG contracts for anthrax detection, and planned launches like a FluA/B, RSV, SARS-CoV-2 panel, with ongoing assay development for sepsis and fungal panels[1][3][4].
Tangen Biosciences emerged from the vision of co-founder John Davidson, PhD, Chief Science Officer with a Harvard biochemistry PhD and 14 years in DNA technologies, including senior roles at Ion Torrent/Life Technologies where he commercialized sequencing platforms[2]. The idea addressed molecular diagnostics' failure to disrupt blood culture for bloodstream infections (BSI) due to poor sensitivity, despite speed advantages; Tangen's team—experienced in revolutionary molecular tools—developed core IP-pending technologies like the LVC™ sample processor, RAMP amplification disk, and GeneSpark™ instrument to enable extreme sensitivity from any sample volume[1][2]. Early traction featured a planned 2019 US launch post-$8M Series A and 510(k) clearance for sepsis, plus contracts like USG anthrax testing, evolving from lab-bound tech to portable solutions amid COVID-19 opportunities[1][2][3].
Tangen rides the point-of-care (POC) diagnostics trend, decentralizing molecular testing from labs to enable rapid pathogen ID amid rising antimicrobial resistance, pandemics, and global health inequities—timing amplified by COVID-19 accelerating BARDA-funded POC needs[1][3][4]. Market forces like the $3B BSI/sepsis diagnostics gap (where molecular tech lagged culture methods) favor its breakthrough sensitivity from unprocessed blood, positioning it against PCR limitations in non-lab settings[2]. It influences the ecosystem by enabling rural/global access, bioterrorism preparedness (e.g., anthrax contracts), and faster antibiotic guidance, potentially transforming outcomes in infectious disease management[1][2].
Tangen's portable, multi-target platform positions it for expansion into sepsis commercialization, new assays (e.g., antibiotic sensitivity from blood in <1 hour), and broader POC adoption as AI-enhanced diagnostics and resistance tracking grow[1][2]. Regulatory wins like 510(k) and more BARDA/USG deals could drive partnerships with pharma or health systems, evolving its influence from niche innovator to sepsis/POCD leader. With momentum from COVID-era validations, expect scaled global impact, circling back to its core promise: high-quality molecular testing anywhere, anytime[3][4].
Tangen Biosciences has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Series A in June 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2019 | $9.0M Series A | Connecticut Innovations, Sway Ventures |